Brain+

0,08

DKK

-15,25 %

BRAINP

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

3 investorer følger denne virksomhed

-15,25%

-15,79%

+0,25%

+8,4%

-56,08%

-58,03%

-95,68%

-

-97,1%

Brain + er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling til behandling af demens og Alzheimers. Produktporteføljen omfatter f.eks. Kognitiv stimuleringsterapi. Forretningen drives med den største tilstedeværelse i Europa.

Markedsværdi

17 mio. DKK

Aktieomsætning

60,19 t DKK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

ViserAlle indholdstyper

Pressemeddelelse10.12.2024, 07.45

Brain+ A/S: Brain+ invites to investor webinar to update on UK commercial pipeline and status

Pressemeddelelse5.12.2024, 07.51

Brain+ A/S: Brain+ secures its first multi-year sales contract for Ayla - your CST Assistant with Syddjurs municipality

Pressemeddelelse21.11.2024, 14.30

Brain+ A/S: Invitation to Investor Webinar on Monday 25th of November at 15:30: Update on commercial status and new opportunities

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse1.11.2024, 10.57

Brain+ A/S: Brain+ closes new Danish municipality sales contract on Ayla - your CST Assistant

Pressemeddelelse21.10.2024, 09.54

Brain+ A/S: Brain+ progresses UK commercial outreach and hosts the first of a series of webinars on the value of Cognitive Stimulation Therapy

Pressemeddelelse11.10.2024, 07.04

Brain+ A/S: Brain+ unveils new visual brand and website to elevate its Ayla Dementia Care solutions

Selskabsmeddelelse7.10.2024, 09.50

Brain+ A/S: Brain+ announces first day of trading in new shares from the TO 4 warrant exercise and the related directed issue

Pressemeddelelse2.10.2024, 08.32

Brain+ A/S: Brain+ launches Ayla - your CST Assistant into the UK dementia market

Selskabsmeddelelse1.10.2024, 10.11

Brain+ A/S: Brain+ announces the outcome of its series TO 4 warrant exercise and the decision to carry out a directed share issue to cover guarantor subscriptions

Pressemeddelelse1.10.2024, 07.23

Brain+ A/S: Ayla - your CST Assistant has been registered in the UK as a certified Medical Device Software for dementia therapy

Pressemeddelelse25.9.2024, 08.43

Brain+ A/S: Brain+ confirms imminent commercial launch of Ayla - your CST Assistant as a medical device in the UK

Pressemeddelelse23.9.2024, 10.15

Brain+ A/S: Brain+ informs of three product releases planned for 2025 and introduces a platform renaming as part of its UK commercialization

Selskabsmeddelelse20.9.2024, 06.43

Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%

Selskabsmeddelelse17.9.2024, 08.46

Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4

Pressemeddelelse13.9.2024, 08.33

Brain+ A/S: Brain+ is set to deliver on an ambitious UK commercial plan to reach recurring revenue of DKK 7-8 million by 2025 and DKK 25-27 million by 2027

Selskabsmeddelelse13.9.2024, 07.08

Brain+ A/S announces the exercise price for its warrants of series TO 4

Pressemeddelelse5.9.2024, 07.30

Brain+ A/S: First patient enrolled in a clinical trial to evaluate Brain+' next generation cognitive training technology for Mild Cognitive Impairment

Pressemeddelelse3.9.2024, 06.30

Brain+ A/S: Results from UK study of the CST-Assistant show clinical relevance, cost-benefit and product-market fit

Pressemeddelelse30.8.2024, 10.35

Brain+ A/S: Invitation to Investor Webinar on Tues 3 Sept 2024 at 16:00 CEST: H1 2024 report and new Chief Commercial Officer

Selskabsmeddelelse29.8.2024, 17.08

Brain+ A/S: H1 2024: Brain+ has executed successfully in accordance with its UK-focused commercial strategy towards proof-of-business and realized financial results as expected

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.